Crinetics Pharmaceuticals agreed to be acquired by Vertex Pharmaceuticals in an all-cash merger at $85.00 per share. The transaction, expected to close in the third quarter of 2026, is subject to stockholder approval, regulatory clearances, and other customary conditions and carries no financing condition. In parallel, Vertex obtained a $4.5 billion unsecured 364-day bridge loan commitment from Bank of America, BofA Securities, and Morgan Stanley Senior Funding to support the deal pending permanent financing. Unvested Crinetics equity awards will vest at closing, with in-the-money options and RSUs cashed out.
Agreement 1: Crinetics to Be Acquired by Vertex in $85-Per-Share All-Cash Deal
- Agreement type: Agreement and Plan of Merger
- Counterparty: Vertex Pharmaceuticals
- Signed / Effective: Jul 06 2026 / Jul 06 2026
- Duration / Termination: Until closing
- Reason: Vertex to acquire Crinetics for strategic growth
Agreement 2: Vertex Lines Up $4.5 Billion Bridge to Finance Crinetics Acquisition
- Agreement type: Unsecured 364-day bridge loan commitment ($4.5 billion)
- Counterparty: Bank of America; BofA Securities; Morgan Stanley Senior Funding
- Signed / Effective: Jul 06 2026 / Jul 06 2026
- Duration / Termination: 364 days
- Reason: Backstop financing for Vertex's acquisition of Crinetics
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.